Cellectar Biosciences (CLRB) Competitors

Cellectar Biosciences logo
$0.89 -0.04 (-3.81%)
Closing price 04:00 PM Eastern
Extended Trading
$0.89 +0.00 (+0.09%)
As of 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CLRB vs. ATHE, UG, INCR, GRCE, and ALDX

Should you buy Cellectar Biosciences stock or one of its competitors? Cellectar Biosciences's main competitors and comparable companies include Alterity Therapeutics (ATHE), United-Guardian (UG), InterCure (INCR), Grace Therapeutics (GRCE), and Aldeyra Therapeutics (ALDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cellectar Biosciences compare to Alterity Therapeutics?

Cellectar Biosciences (NASDAQ:CLRB) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Alterity Therapeutics' return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectar BiosciencesN/A -163.85% -111.83%
Alterity Therapeutics N/A N/A N/A

Cellectar Biosciences presently has a consensus price target of $11.00, indicating a potential upside of 1,095.26%. Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 436.19%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Cellectar Biosciences is more favorable than Alterity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Cellectar Biosciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

In the previous week, Cellectar Biosciences had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Cellectar Biosciences and 2 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.89 beat Cellectar Biosciences' score of 0.68 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cellectar Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alterity Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectar BiosciencesN/AN/A-$21.79M-$2.89N/A
Alterity TherapeuticsN/AN/A-$15.88MN/AN/A

Summary

Cellectar Biosciences and Alterity Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Cellectar Biosciences compare to United-Guardian?

United-Guardian (NASDAQ:UG) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

United-Guardian has a net margin of 25.16% compared to Cellectar Biosciences' net margin of 0.00%. United-Guardian's return on equity of 27.84% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
United-Guardian25.16% 27.84% 23.68%
Cellectar Biosciences N/A -163.85%-111.83%

United-Guardian has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

United-Guardian has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United-Guardian$10.55M3.29$2.11M$0.6811.12
Cellectar BiosciencesN/AN/A-$21.79M-$2.89N/A

In the previous week, Cellectar Biosciences had 3 more articles in the media than United-Guardian. MarketBeat recorded 3 mentions for Cellectar Biosciences and 0 mentions for United-Guardian. United-Guardian's average media sentiment score of 0.94 beat Cellectar Biosciences' score of 0.68 indicating that United-Guardian is being referred to more favorably in the media.

Company Overall Sentiment
United-Guardian Positive
Cellectar Biosciences Positive

23.2% of United-Guardian shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 29.0% of United-Guardian shares are held by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 1,095.26%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than United-Guardian.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United-Guardian
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cellectar Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

United-Guardian beats Cellectar Biosciences on 10 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to InterCure?

Cellectar Biosciences (NASDAQ:CLRB) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

InterCure's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectar BiosciencesN/A -163.85% -111.83%
InterCure N/A N/A N/A

Cellectar Biosciences has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, InterCure has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Cellectar Biosciences presently has a consensus price target of $11.00, suggesting a potential upside of 1,095.26%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than InterCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
InterCure
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

InterCure has higher revenue and earnings than Cellectar Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectar BiosciencesN/AN/A-$21.79M-$2.89N/A
InterCure$78.47M0.50-$10.37MN/AN/A

In the previous week, Cellectar Biosciences had 3 more articles in the media than InterCure. MarketBeat recorded 3 mentions for Cellectar Biosciences and 0 mentions for InterCure. InterCure's average media sentiment score of 0.89 beat Cellectar Biosciences' score of 0.68 indicating that InterCure is being referred to more favorably in the news media.

Company Overall Sentiment
Cellectar Biosciences Positive
InterCure Positive

Summary

Cellectar Biosciences beats InterCure on 7 of the 13 factors compared between the two stocks.

How does Cellectar Biosciences compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Grace Therapeutics' return on equity of -37.00% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Grace TherapeuticsN/A -37.00% -35.53%
Cellectar Biosciences N/A -163.85%-111.83%

Grace Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 248.84%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 1,095.26%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Grace Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grace Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cellectar Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 10.8% of Grace Therapeutics shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Grace Therapeutics had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 5 mentions for Grace Therapeutics and 3 mentions for Cellectar Biosciences. Grace Therapeutics' average media sentiment score of 0.81 beat Cellectar Biosciences' score of 0.68 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Grace Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cellectar Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Grace Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grace TherapeuticsN/AN/A-$7.79M-$1.23N/A
Cellectar BiosciencesN/AN/A-$21.79M-$2.89N/A

Grace Therapeutics has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Summary

Grace Therapeutics beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks.

How does Cellectar Biosciences compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Aldeyra Therapeutics' return on equity of -47.97% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aldeyra TherapeuticsN/A -47.97% -33.34%
Cellectar Biosciences N/A -163.85%-111.83%

Aldeyra Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, Aldeyra Therapeutics had 8 more articles in the media than Cellectar Biosciences. MarketBeat recorded 11 mentions for Aldeyra Therapeutics and 3 mentions for Cellectar Biosciences. Aldeyra Therapeutics' average media sentiment score of 0.79 beat Cellectar Biosciences' score of 0.68 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aldeyra Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cellectar Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aldeyra TherapeuticsN/AN/A-$33.85M-$0.32N/A
Cellectar BiosciencesN/AN/A-$21.79M-$2.89N/A

Aldeyra Therapeutics currently has a consensus price target of $2.00, suggesting a potential upside of 188.23%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 1,095.26%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Aldeyra Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aldeyra Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cellectar Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Aldeyra Therapeutics beats Cellectar Biosciences on 8 of the 13 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLRB vs. The Competition

MetricCellectar BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9.24M$13.38B$7.60B$11.72B
Dividend YieldN/A2.58%2.47%4.48%
P/E RatioN/A27.9733.5830.13
Price / SalesN/A6.798.275.60
Price / CashN/A15.6321.0121.90
Price / Book0.405.394.443.72
Net Income-$21.79M$2.88B$3.50B$393.88M
7 Day Performance-26.84%-5.24%-6.53%-6.07%
1 Month Performance-22.35%-4.80%-4.93%-7.38%
1 Year Performance-71.17%-7.35%-1.73%-7.48%

Cellectar Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLRB
Cellectar Biosciences
2.7058 of 5 stars
$0.89
-3.8%
$11.00
+1,142.7%
-68.5%$9.24MN/AN/A11
ATHE
Alterity Therapeutics
3.0443 of 5 stars
$2.32
-4.5%
$10.00
+331.0%
-50.8%$42.06MN/AN/A11
UG
United-Guardian
1.6028 of 5 stars
$9.16
+3.5%
N/A+23.9%$42.04M$10.55M16.9625
INCR
InterCure
0.4273 of 5 stars
$3.82
+5.3%
N/A-47.3%$41.84M$78.47MN/A285
GRCE
Grace Therapeutics
1.9345 of 5 stars
$1.86
-0.3%
$6.00
+222.6%
-42.7%$39.13MN/AN/A5

Related Companies and Tools


This page (NASDAQ:CLRB) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners